Literature DB >> 2671601

Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus.

J L Selam1, M Kashyap, K G Alberti, J Lozano, M Hanna, D Turner, N Jeandidier, E Chan, M A Charles.   

Abstract

The relative biologic efficacy of intraperitoneal (IP) insulin administration over peripheral routes of insulin infusion for artificial delivery devices is still poorly documented. Thus, the effects of IP insulin administration have been compared with the effects of subcutaneous (SC) insulin administration upon circulating fuel metabolites, hormones and lipoproteins. In a longitudinal study, seven type I diabetic patients, aged 33 +/- 3 years, duration 16 +/- 4 years, were studied. SC intensive insulin therapy was used for 3 months, then insulin was infused IP via an implantable pump for 6 months with a similar good blood glucose control. Lipids including high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) cholesterol, apolipoproteins A-I, A-II, and B were measured every 3 months. Although all values remained in the normal range, significant changes occurred in plasma triglycerides (63 +/- 9 SC v 88 +/- 12 mg/dL IP, P less than .05) and HDL-cholesterol (57 +/- 4 SC v 42 +/- 4 mg/dL IP, P less than .05) without concomitant changes in apolipoprotein levels. In another cross-sectional study, six of the patients consumed a standardized 400 kcal breakfast after 0.15 U/kg insulin. Eight SC insulin infused age-, glucose control- and weight-matched diabetic patients also underwent the same test using SC insulin. Six normal subjects consumed the same breakfast and served as controls. Plasma glucose, B-hydroxybutyrate, lactate, alanine, free fatty acids, free insulin and glucagon were measured for five hours after the meal. All measured parameters were comparable in both groups except free insulin and lactate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2671601     DOI: 10.1016/0026-0495(89)90240-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  7 in total

1.  A New Optimized Percutaneous Access System for CIPII.

Authors:  Rosa Garcia-Verdugo; Michael Erbach; Oliver Schnell
Journal:  J Diabetes Sci Technol       Date:  2017-03-01

Review 2.  Cardiovascular risk in double diabetes mellitus--when two worlds collide.

Authors:  Stephen J Cleland
Journal:  Nat Rev Endocrinol       Date:  2012-04-10       Impact factor: 43.330

Review 3.  Finding the right route for insulin delivery - an overview of implantable pump therapy.

Authors:  Lia Bally; Hood Thabit; Roman Hovorka
Journal:  Expert Opin Drug Deliv       Date:  2016-12-07       Impact factor: 6.648

Review 4.  Insulin resistance in type 1 diabetes: what is 'double diabetes' and what are the risks?

Authors:  S J Cleland; B M Fisher; H M Colhoun; N Sattar; J R Petrie
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

Review 5.  Implantable insulin pumps and metabolic control.

Authors:  K D Hepp
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

6.  Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A systematic review and meta-analysis.

Authors:  Ilze Dirnena-Fusini; Marte Kierulf Åm; Anders Lyngvi Fougner; Sven Magnus Carlsen; Sverre Christian Christiansen
Journal:  PLoS One       Date:  2021-04-13       Impact factor: 3.240

7.  Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.

Authors:  M J Davies; D Russell-Jones; J-L Selam; T S Bailey; Z Kerényi; J Luo; J Bue-Valleskey; T Iványi; M L Hartman; J G Jacobson; S J Jacober
Journal:  Diabetes Obes Metab       Date:  2016-08-12       Impact factor: 6.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.